Patents by Inventor Richard Gibson
Richard Gibson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12312946Abstract: A method can be used to determine multi-phase measurements of fluid flowing with respect to a wellbore. Signals can be received, and the signals can be emitted by each variable frequency acoustic emitter of a set of variable frequency acoustic emitters positioned spaced apart in a sensing transducer that is in an interior of a wellbore. The received signals can be converted into a flow rate of each of a set of different fluid phases of a fluid in the wellbore. The multi-phase measurements of the fluid can be determined using the converted flow rate.Type: GrantFiled: June 3, 2022Date of Patent: May 27, 2025Assignee: Halliburton Energy Services, Inc.Inventors: Julian Drew, David Diller, Werner Heigl, Richard Gibson, Jr., Barry Fish
-
Publication number: 20250102357Abstract: Tunable or swept cat's-eye lasers for spectroscopy that is adapted for direct mounting to a flow cell and/or includes an internal gas cell and is appropriate for installation in adverse environments and capable of automated alignment and installation in explosion proof enclosures.Type: ApplicationFiled: September 25, 2024Publication date: March 27, 2025Inventors: Walid A. Atia, Richard Gibson-Dee
-
Patent number: 11993595Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.Type: GrantFiled: September 1, 2022Date of Patent: May 28, 2024Assignee: Mission Therapeutics LimitedInventors: Alison Jones, Mark Ian Kemp, Martin Lee Stockley, Karl Richard Gibson, Gavin Alistair Whitlock, Andrew Madin
-
Patent number: 11970939Abstract: Aspects of the subject technology relate to systems, methods, and computer-readable media for machine learning analysis of low-frequency signal data in fracturing operations. The present technology can receive strain data associated with a monitoring well that is proximate to a treatment well. The strain data can comprise information representing a fracturing operation associated with the treatment well. Further, the present technology can convert the strain data into image data where a color scale corresponds to a degree of strain observed by a fiber optic cable deployed in the monitoring well. As follows, the present technology can provide the image data to a machine-learning model, which is configured to identify one or more features in the image data.Type: GrantFiled: July 15, 2022Date of Patent: April 30, 2024Assignee: HALLIBURTON ENERGY SERVICES, INC.Inventors: Benjamin Schaeffer, Mikko K. Jaaskelainen, Richard Gibson
-
Publication number: 20240018866Abstract: Aspects of the subject technology relate to systems, methods, and computer-readable media for machine learning analysis of low-frequency signal data in fracturing operations. The present technology can receive strain data associated with a monitoring well that is proximate to a treatment well. The strain data can comprise information representing a fracturing operation associated with the treatment well. Further, the present technology can convert the strain data into image data where a color scale corresponds to a degree of strain observed by a fiber optic cable deployed in the monitoring well. As follows, the present technology can provide the image data to a machine-learning model, which is configured to identify one or more features in the image data.Type: ApplicationFiled: July 15, 2022Publication date: January 18, 2024Applicant: Halliburton Energy Services, Inc.Inventors: Benjamin SCHAEFFER, Mikko K. JAASKELAINEN, Richard GIBSON
-
Publication number: 20230316815Abstract: A system may include a processor to receive vehicle data from a vehicle system at a first location and communicate the data to a second location. The processor may integrate the data into a database of diagnostic data at the second location and identify a diagnostic code that indicates an expected operation of the vehicle system or an unexpected operation. The processor may determine a maintenance operation based on the diagnostic code. A method may include receiving vehicle data from a vehicle system at a first location and communicating the vehicle data to a second location. The method may include integrating the vehicle data into a database of first diagnostic data and identifying a diagnostic code that indicates whether the vehicle data represents an expected operation of the vehicle system or an unexpected operation of the vehicle system. The method may include determining a maintenance operation based on the code.Type: ApplicationFiled: March 31, 2022Publication date: October 5, 2023Inventors: Nicholas Roddy, Umang Gopalbhai Brahmakshatriya, Hammad Shaikh, Yoshita Jain, John Lahut, Benedict Lander, David Richard Gibson, Bernhard J. Scholz, David Joseph Schroeck, Jason Quigley
-
Patent number: 11660293Abstract: There is provided a compound of formula (I), wherein L1 to L3?, R1 to R4, X, A and B have meanings given in the description, and pharmaceutically acceptable salts, solvates and prodrugs thereof, which compounds are useful as antagonists of the orexin-1 and orexin-2 receptors or as selective antagonists of the orexin-1 receptor, and thus, in particular, in the treatment or prevention of inter alia substance dependence, addiction, anxiety disorders, panic disorders, binge eating, compulsive disorders, impulse control disorders, cognitive impairment and Alzheimer's disease.Type: GrantFiled: August 31, 2018Date of Patent: May 30, 2023Assignee: CHRONOS THERAPEUTICS LIMITEDInventors: Fabrizio Micheli, Barbara Bertani, Karl Richard Gibson, Romano Di Fabio, Luca Raveglia, Riccardo Zanaletti, Susanna Cremonesi, Alfonso Pozzan, Teresa Semeraro, Luca Tarsi, Timothy Jon Luker
-
Publication number: 20230144034Abstract: A method can be used to determine multi-phase measurements of fluid flowing with respect to a wellbore. Signals can be received, and the signals can be emitted by each variable frequency acoustic emitter of a set of variable frequency acoustic emitters positioned spaced apart in a sensing transducer that is in an interior of a wellbore. The received signals can be converted into a flow rate of each of a set of different fluid phases of a fluid in the wellbore. The multi-phase measurements of the fluid can be determined using the converted flow rate.Type: ApplicationFiled: June 3, 2022Publication date: May 11, 2023Inventors: Julian Drew, David Diller, Werner Heigl, Richard Gibson, JR., Barry Fish
-
Publication number: 20230052191Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.Type: ApplicationFiled: September 1, 2022Publication date: February 16, 2023Inventors: Alison Jones, Mark Ian Kemp, Martin Lee Stockley, Karl Richard Gibson, Gavin Alistair Whitlock, Andrew Madin
-
Publication number: 20230036854Abstract: Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: wherein R1, R2, R4, R5, R6, R7, R8, R9, R10, Z, X1, X2, X3, L2, HET, n and q are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.Type: ApplicationFiled: November 15, 2019Publication date: February 2, 2023Inventors: Gareth RICHARDS, Timothy M. SKERRY, Joseph P.A. HARRITY, Jean-Olivier ZIRIMWABAGABO, Matthew J. TOZER, Karl Richard GIBSON, Roderick Alan PORTER, Paul Alan GLOSSOP
-
Publication number: 20220331299Abstract: There is provided a compound of formula (I), wherein L1 to L3?, R1 to R4, X, A and B have meanings given in the description, and pharmaceutically acceptable salts, solvates and prodrugs thereof, which compounds are useful as antagonists of the orexin-1 and orexin-2 receptors or as selective antagonists of the orexin-1 receptor, and thus, in particular, in the treatment or prevention of inter alia substance dependence, addiction, anxiety disorders, panic disorders, binge eating, compulsive disorders, impulse control disorders, cognitive impairment and Alzheimer's disease.Type: ApplicationFiled: August 31, 2018Publication date: October 20, 2022Inventors: Fabrizio Micheli, Barbara Bertani, Karl Richard Gibson, Romano Di Fabio, Luca Raveglia, Riccardo Zanaletti, Susanna Cremonesi, Alfonso Pozzan, Teresa Semeraro, Luca Tarsi, Timothy Jon Luker
-
Patent number: 11472798Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.Type: GrantFiled: August 11, 2020Date of Patent: October 18, 2022Assignee: MISSION THERAPEUTICS LTDInventors: Alison Jones, Mark Ian Kemp, Martin Lee Stockley, Karl Richard Gibson, Gavin Alistair Whitlock, Andrew Madin
-
Patent number: 11400081Abstract: Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein R1, R2, R3, R4, R5, R6, R8, R9, X, X1, X2, X3, L1 and n are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.Type: GrantFiled: May 16, 2018Date of Patent: August 2, 2022Assignee: The University of SheffieldInventors: Gareth Richards, Timothy M. Skerry, Joseph P. A. Harrity, Jean-Olivier Zirimwabagabo, Matthew J. Tozer, Karl Richard Gibson, Roderick Alan Porter, Paul Matthew Blaney, Paul Alan Glossop
-
Publication number: 20220169653Abstract: The present invention relates to pyrrolopyrimidine compounds according to Formula I and their use in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases. In a particular aspect, the present compounds are ASK inhibitors, particularly ASK1 inhibitors. The present invention also provides methods for the production of a compound of the invention, pharmaceutical compositions comprising a compound of the invention, the use of the compounds in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases.Type: ApplicationFiled: September 3, 2021Publication date: June 2, 2022Inventors: David AMANTINI, Milan MESIC, Gordon SAXTY, Tanja POLJAK, Ines VUJASINOVIC, Dinko ZIHER, David WITTY, Karl Richard GIBSON
-
Publication number: 20220023281Abstract: Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: wherein HET, R1, R2, R3, R4, R5, L, L1, X1, X2, X3 and q are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.Type: ApplicationFiled: November 15, 2019Publication date: January 27, 2022Inventors: Gareth RICHARDS, Timothy M. SKERRY, Joseph P.A. HARRITY, Jean-Olivier ZIRIMWABAGABO, Matthew J. TOZER, Karl Richard GIBSON, Roderick Alan PORTER, Paul Alan GLOSSOP
-
Patent number: 11136325Abstract: The present invention relates to pyrrolopyrimidine compounds according to Formula I and their use in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases. In a particular aspect, the present compounds are ASK inhibitors, particularly ASK1 inhibitors. The present invention also provides methods for the production of a compound of the invention, pharmaceutical compositions comprising a compound of the invention, the use of the compounds in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases.Type: GrantFiled: July 12, 2018Date of Patent: October 5, 2021Assignee: GALAPAGOS NVInventors: David Amantini, Milan Mesic, Gordon Saxty, Tanja Poljak, Ines Vujasinovic, Dinko Ziher, David Witty, Karl Richard Gibson
-
Patent number: 11025553Abstract: Conventional internet routing is handled using routing protocols such as the Border Gateway Protocol (BGP). However, simple BGP does not account for latency, packet loss, or cost. To address this problem, smart routing systems that route traffic fast and in a cost-effective manner are implemented. In one approach, smart routing systems measure, compare, and analyze round-trip latencies and other metrics between a customer premises and one or more endpoints. Optimal inbound and outbound transit providers are selected for each endpoint based on these measurements. Other smart routing systems collect and analyze Real User Monitoring (RUM) data to predict latency performance of different content origins for serving data to a particular client based on the client's IP address and the content origins' IP addresses, which are ranked by performance.Type: GrantFiled: April 21, 2020Date of Patent: June 1, 2021Assignee: Dynamic Network Services, Inc.Inventors: Alin Popescu, Philip Stanhope, Arun Mehra, Stephen Hulshof, Brian Premore, Douglas Madory, Scott Michael Brazina, Charlie Baker, Richard Gibson
-
Publication number: 20210113534Abstract: Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein R1, R2, R3, R4, R5, R6, R8, R9, X, X1, X2, X3, L1 and n are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.Type: ApplicationFiled: May 16, 2018Publication date: April 22, 2021Inventors: Gareth Richards, Timothy M. Skerry, Joseph P.A. Harrity, Jean-Olivier Zirimwabagabo, Matthew J. Tozer, Karl Richard Gibson, Roderick Alan Porter, Paul Matthew Blaney, Paul Alan Glossop
-
Publication number: 20200369658Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.Type: ApplicationFiled: August 11, 2020Publication date: November 26, 2020Inventors: Alison Jones, Mark Ian Kemp, Martin Lee Stockley, Karl Richard Gibson, Gavin Alistair Whitlock, Andrew Madin
-
Patent number: 10774078Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.Type: GrantFiled: June 21, 2019Date of Patent: September 15, 2020Assignee: MISSION THERAPEUTICS LTDInventors: Alison Jones, Mark Ian Kemp, Martin Lee Stockley, Karl Richard Gibson, Gavin Alistair Whitlock, Andrew Madin